Advertisement
The incidence of paradoxical adipose hyperplasia following cryolipolysis may be higher than previously described

Higher Incidence of Paradoxical Adipose Hyperplasia Reported

0
Two case reports in single practice indicate incidence of 0.47 percent; higher than described previously
Millions more Americans have affordable health insurance

Patients Report Improved Care Access, Better Health With ACA

0
Gains seen in how many adults have insurance and a doctor, and say they are in better health
Self- and caregiver-reported history of eczema is valid for identifying atopic dermatitis

Self-Reported Eczema Valid for Detecting Atopic Dermatitis

0
High specificity and positive predictive value for self-, caregiver-reported ever history of eczema
Confetti-like depigmentation may be a marker of rapidly progressing vitiligo

Confetti-Like Depigmentation May Predict Vitiligo Progression

0
Review finds confetti-like pattern may predict rapid disease progression
About 10 percent of cases where a drug does serious harm are not reported to the U.S. Food and Drug Administration within the required 15-day period

Delays Noted in the Reporting of Serious Patient Harms to FDA

0
Analysis found roughly 10 percent of cases were filed after 15-day deadline passed
Topical application of human breast milk is effective for infants with mild to moderate atopic dermatitis

Human Breast Milk Effective for Atopic Dermatitis in Infants

0
No significant difference in outcomes for human breast milk, 1 percent hydrocortisone ointment
As a result of the increasing popularity of high-deductible health care plans

Expansion of High-Deductible Plans to Impact Physician Care

0
Physicians must be able to balance provision of good clinical care with ability to limit costs
Odomzo (sonidegib) has been approved by the U.S. Food and Drug Administration to treat locally advanced basal cell carcinoma that has returned despite surgery or radiation. The treatment is sanctioned for people who are not candidates for additional surgery or radiation.

FDA Approves Odomzo for Recurring Basal Cell Carcinoma

0
Medication is designed to inhibit the Hedgehog pathway
An 810- and 940-nm diode laser is safe and efficacious for treating facial skin laxity

Diode Laser Safe, Effective for Treating Facial Skin Laxity

0
Significant improvements in laxity of facial skin at one and three months after treatment
Picosecond-domain Nd:YAG laser incorporating a potassium-titanyl-phosphate frequency-doubling crystal is safe and effective for removing decorative tattoos

Picosecond-Domain Laser Safe for Removing Decorative Tattoos

0
Average clearance of 79 percent after 6.5 treatments for 21 subjects with 31 decorative tattoos